| B32 | High rates of viral suppression sixteen weeks after transition from EFV- to DTG-based ART regardless of viral load at transition: the DO-REAL cohort study in Lesotho | E-poster | ART in first- and second-line therapies |
| B32 | The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: results from the DRIVE-AHEAD clinical trial | E-poster | ART in first- and second-line therapies |
| B32 | Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in treatment-experienced HIV-1 infected patients: week 48 analysis from the randomized controlled phase 3 TALENT study | E-poster | ART in first- and second-line therapies |
| B32 | Week 96 metabolic and bone outcomes of a Phase 2b trial of islatravir and doravirine | E-poster | ART in first- and second-line therapies |
| B32 | Achievement of undetectable HIV-1 RNA in the B/F/TAF treatment-naïve clinical trials | E-poster | ART in first- and second-line therapies |
| B32 | Long-term analysis of B/F/TAF in treatment-naïve adults living with HIV through four years of follow-up | E-poster | ART in first- and second-line therapies |
| B33 | Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) | Oral abstract session with live Q&A | ART in highly treatment-experienced people |
| B33 | Transition to TLD leads to decreased rates of virologic failure among PLWH in sub-Saharan Africa | E-poster | ART in highly treatment-experienced people |
| B33 | Long-term (96-week) safety of fostemsavir (FTR) in heavily treatment-experienced (HTE) adults infected with multidrug-resistant (MDR) HIV-1 (BRIGHTE Phase 3 study) | E-poster | ART in highly treatment-experienced people |
| B33 | Weight changes in HIV+ individuals receiving ibalizumab over 96 weeks | E-poster | ART in highly treatment-experienced people |